Continuous manufacturing has attracted significant interest over the past decade for small molecules formulated as drug products. The case for adopting continuous manufacturing platforms for manufacturing biologics (i.e., large proteins or biologic products such as vaccines) would, in principle, be...
The topic of continuous manufacturing has drawn considerable interest across all modalities of pharmaceutical manufacturing. Thus far much of the progress has been seen in small molecule drug product manufacturing platforms where multiple products have...
When we first launched the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) in 2017, we benefited from an incredible enthusiasm and engagement from across the ecosystem. At the time, academic institutions were working to...
It’s hard to believe, but it was 10 years ago when I gave my first presentation on continuous manufacturing for pharmaceuticals. It was at the ISPE Nordic Conference in Copenhagen in 2010, and I was still at FDA at the time. Looking back, it’s...
